Page 19 - reflections_newsletter10

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #10 2025

Abbreviations Dyslipidaemia
AAV, adeno-associated viral; ABE, adenine base editing; ABI, ankle brachial index; ACC, American College of Cardiology; acetyl-
CoA, acetyl coenzyme A; ACLY, ATP citrate lyase; ACS, acute coronary syndrome; AHA, American Heart Association; ANGPTL3,
angiopoietin-related protein 3; apoB, apolipoprotein B; APOC3, apolipoprotein C3 gene; APOC3, apolipoprotein C3; ASCVD,
atherosclerotic cardiovascular disease; ASGPR, asialoglycoprotein receptor; ASO, antisense oligonucleotide; ATP, adenosine
triphosphate; AU, Agatston units; BA, bempedoic acid; BIOmarCare, Biomarker for Cardiovascular Risk Assessment across Europe;
BM, biomarkers; BMI, body mass index; Cas9, CRISPR-associated protein 9; CETP, cholesteryl ester transfer protein; CHD,
coronary heart disease; Chol, cholesterol; CI, confidence interval; CRISPR, clustered regularly interspaced short palindromic repeats;
CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; EAS, European Atherosclerosis Society; EL,
endothelial lipase; ESC, European Society of Cardiology; EZE, ezetimibe; FCS, in familial chylomicronaemia syndrome; FFA, free
fatty acid; FGF21, fibroblast growth factor 21; FH, familial hypercholesterolaemia; GaINAc, N-acetylgalactosamine; GIP, glucose-
dependent insulinotropic polypeptide; GLP1, glucagon-like peptide-1; gRNA, guide RNA; HDL-C, high-density lipoprotein cholesterol;
HeFH, heterozygous familial hypercholesterolaemia; HIV, human immunodeficiency virus; HMG-CoAR, 3-hydroxy-3-methylglutaryl
coenzyme A reductase; HoFH, homozygous familial hypercholesterolaemia; HR, hazard ratio; hsCRP, high-sensitivity C-reactive
protein; hs-TnI, high-sensitivity troponin I; LDL-C, low-density lipoprotein cholesterol; LDLR, LDL receptor; LLT, lipid-lowering therapy;
LPA, lipoprotein a gene; Lp(a), lipoprotein a; LPL, lipoprotein lipase; m, messenger; mAb, monoclonal antibody; MACE, major
adverse cardiovascular event; MI, myocardial infarction; ML, machine learning; MORGAM, MOnica Risk, Genetics, Archiving and
Monograph; MTP, microsomal triglyceride transfer protein; NLA, National Lipid Association; non-HDL-C, non-high-density lipoprotein
cholesterol; NPC1L1, Niemann-Pick C1-like 1; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OxPL, oxidised phospholipids;
PCSK9, proprotein convertase subtilisin/kexin type 9; PRS, polygenic risk score; Q2W, every 2 weeks; RCT, randomised controlled
trial; remnant-C, remnant cholesterol; RISC, RNA-induced silencing complex; RNA, ribose nucleic acid; SCORE2, Systematic
Coronary Risk Evaluation 2; SCORE2-OP, Systematic Coronary Risk Evaluation 2-Older Persons; sHR, subdistribution hazard ratio;
sHTG, severe hypertriglyceridaemia; si, small interfering; TG, triglyceride; TRL, triglyceride-rich lipoproteins; VLDL, very low-density
lipoprotein.

TABLE OF CONTENTS